# From measurement to decision: a tissue-aware digital-twin platform for CAR T cell dosimetry

S. de la Torre Gonzalez[1], L. Breitwieser[2,3], X. Fu[4], C. Miller[4], K. Keeshan[5], H. Donnelly[5], C. Halsey[5], V. Cowling[4], M. Carlevaro[6], E. Lomba[7], V. Vassilev[8], E. Roberts[4], **L.M. Luque[4,9]***

CANCER RESEARCH UK | Scotland Institute

Together we are beating cancer

Problem & Gap

Agent-based models (ABM), are powerful scaffolds for personalised medicine. As **digital twins**, they let us:

- Trial dosimetry strategies
- Generate and test wet-lab hypotheses
- Reduce exploratory animal use

But ABM only become **robust enough to guide treatment dose, timing and route** when calibrated and validated using **tissue-resolved measurements**. Those measurements remain **scarce and fragmented**, leaving many existing models **illustrative rather than actionable**.

What we are doing

▷ We're building a **hybrid lab** that integrates **dry lab, wet lab, and software/data delivery.** We generate the **tissue-resolved measurements** (time points, spatial distributions, biomechanics) needed to **calibrate and validate** our CAR T digital twin, and we curate **standardised, shareable datasets** for the community.

▷ In parallel, we run our ABM as the **BioDynaMo** engine on **HPC** with a **user-friendly UI**, so non-coders can test treatment **dose, fractionation, and route** rapidly.

▷ The outcome is a **tissue-aware digital-twin loop—fast, interpretable, and designed to reach patients.**

Agent-Based Model: CAR T cell digital twin

One Dose: increasing cellular dosage does not always increase efficacy


**Multiple dosing** to prevent CAR T cells hypofunction

Wet-Lab: CAR T cell functioning and persistence

We will quantify CAR T functionality and persistence across tissues and different dosimetry strategies, using multimodal assays in B cell Acute Lymphoblastic Leukaemia models

Organ-to-organ Atlas of CAR T cells function

Dosimetry Strategy

Biomechanics

CARTopiaX: BioDynaMo implementation

Our ABM powers BioDynaMo, an open-source platform for creating, running, and visualising 3D agent-based simulations, delivering HPC-class performance, modular reproducibility, and an accessible interface.

CARTopiaX reproduces the tumour growth and CAR T cell therapy administration of our ABM.

2x faster, even pre-optimisation. Preliminary benchmark (Ryzen 5 3600, 6C/12T, 16 GB): **CARTopiaX 8,9 h** vs **ABM 18,8 h.**

1. Google Summer of Code Intern, Universidad de Sevilla, Spain. 2.ETH Zurich, Switzerland. 3.CERN, Geneva, Switzerland. 4.CRUK Scotland Institute, Glasgow, United Kingdom. 5.School of Cancer Sciences, University of Glasgow, United Kingdom. 6.Instituto de Física de Líquidos y Sistemas Biológicos, La Plata, Argentina. 7.Instituto de Química Física Blas Cabrera, Madrid, Spain. 8.Princeton University at CERN, Geneva, Switzerland. 9.CRUK Scotland Centre, Edinburgh, United Kingdom.
Contact: l.luque@crukscotlandinstitute.ac.uk

Read more about me and my research here :)

SCAN ME